The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment

Yale University60 enrolled

Overview

HIV drug resistance presents a significant public heath problem. This proposal is designed to explore the association between ongoing illicit drug use and the prevalence of HIV drug resistance among HIV+ opioid dependent patients receiving opioid agonist treatment with the following hypotheses: 1. Hypothesis 1: The prevalence of HIV drug resistance will range between 10% and 30%. 2. Hypothesis 2: Patients with evidence of ongoing illicit drug use will be more likely to have HIV drug resistance.

Study Type

OBSERVATIONAL

Enrollment

Conditions

HIV Positive Opioid Dependence Opioid Agonist Treatment HIV Infections

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HIV+ * Opioid dependent * Receiving methadone or buprenorphine for at least one month Exclusion Criteria: * age \< 18 years * current dementia; * inability to read or understand English * inability to provide written informed consent

Locations (1)

Outcomes

Primary Outcomes

HIV drug resistance

Time frame: Cross sectional

Secondary Outcomes

Illicit drug use

Time frame: 6 months

HIV transmission risk behaviors

Time frame: 1 year